• New data on IIQ's ovarian cancer test presented at ASCO 2025
• Test achieved 77% sensitivity at 99.6% specificity for all stages
• Test accurately detected all early-stage I and II cancers

INOVIQ Limited (ASX: IIQ) announced the presentation of new data on its EXO-OC™ ovarian cancer test at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 in Chicago. The test, which uses proprietary technology to isolate exosomes and combines multiple exosomal biomarkers in an AI-enhanced algorithm, demonstrated 77% sensitivity at 99.6% specificity for the detection of ovarian cancer across all stages. Importantly, the test accurately detected all Stage I and II ovarian cancers, with no missed early-stage diagnoses. Ovarian cancer is often diagnosed at a late stage, resulting in a 5-year survival rate of only 49%. Early detection may increase 5-year survival from 30% to 93%. INOVIQ has filed an Australian Provisional Patent Application to secure intellectual property rights covering the test. The company plans to conduct validation studies, seek regulatory approvals, and commercialize the test as a Laboratory Developed Test in the US, followed by an In Vitro Diagnostic product.

INOVIQ's EXO-OC test demonstrated 77% sensitivity at 99.6% specificity for detecting ovarian cancer across all stages, including 100% accuracy for early-stage I and II cancers. The company plans to further develop and commercialize the test.

INOVIQ is focused on the rapid commercialization of its EXO-OC test, first as a Laboratory Developed Test and then as a regulatory approved In Vitro Diagnostic for ovarian cancer screening. The company believes the test has the potential to transform precision oncology and save women's lives by enabling earlier diagnosis and intervention.